MediFind
Condition

Aniridia

Condition 101

What is the definition of Aniridia?

Aniridia is an eye disorder characterized by a complete or partial absence of the colored part of the eye (the iris). These iris abnormalities may cause the pupils to be abnormal or misshapen. Aniridia can cause reduction in the sharpness of vision (visual acuity) and increased sensitivity to light (photophobia).People with aniridia can also have other eye problems. Increased pressure in the eye (glaucoma) typically appears in late childhood or early adolescence. Clouding of the lens of the eye (cataracts), occur in 50 percent to 85 percent of people with aniridia. In about 10 percent of affected people, the structures that carry information from the eyes to the brain (optic nerves) are underdeveloped. Individuals with aniridia may also have involuntary eye movements (nystagmus) or underdevelopment of the region at the back of the eye responsible for sharp central vision (foveal hypoplasia). Many of these eye problems contribute to progressive vision loss in affected individuals. The severity of symptoms is typically the same in both eyes.Rarely, people with aniridia have behavioral problems, developmental delay, and problems detecting odors.

What are the causes for Aniridia?

Aniridia is caused by mutations in the PAX6 gene. The PAX6 gene provides instructions for making a protein that is involved in the early development of the eyes, brain and spinal cord (central nervous system), and the pancreas. Within the brain, the PAX6 protein is involved in the development of a specialized group of brain cells that process smell (the olfactory bulb). The PAX6 protein attaches (binds) to specific regions of DNA and regulates the activity of other genes. On the basis of this role, the PAX6 protein is called a transcription factor. Following birth, the PAX6 protein regulates several genes that likely contribute to the maintenance of different eye structures.Mutations in the PAX6 gene result in the production of a nonfunctional PAX6 protein that is unable to bind to DNA and regulate the activity of other genes. A lack of functional PAX6 protein disrupts the formation of the eyes during embryonic development.

How prevalent is Aniridia?

Aniridia occurs in 1 in 50,000 to 100,000 newborns worldwide.

Is Aniridia an inherited disorder?

Aniridia is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.In approximately two-thirds of cases, an affected person inherits the mutation from one affected parent. The remaining one-third of cases result from new mutations in the gene and occur in people with no history of the disorder in their family.

Top Global Doctors

Latest Research

Latest Advance
Study
  • Condition: Iris Defects
  • Journal: PloS one
  • Treatment Used: Iris Reconstruction using an Artificial Iris (AI)
  • Number of Patients: 79
  • Published —
This study evaluated the aesthetic outcome of iris reconstruction using an artificial iris (AI) in patients with large iris defects.
Latest Advance
Study
  • Condition: Multicentric or Bilaterally Predisposed Unilateral Wilm's Tumor
  • Journal: Cancer
  • Treatment Used: Nephrectomy
  • Number of Patients: 34
  • Published —
This study tested the safety and efficacy of using a nephrectomy to treat patients with multicentric or bilaterally predisposed unilateral Wilm's tumor.
Latest Advance
Study
  • Condition: Congenital aniridia
  • Journal: Journal of cataract and refractive surgery
  • Treatment Used: Prosthetic iris device
  • Number of Patients: 50
  • Published —
The study researched the long-term outcomes of a prosthetic iris device for patients with congenital aniridia.
Latest Advance
Study
  • Condition: Aniridia-Related Glaucoma
  • Journal: Turkish journal of ophthalmology
  • Treatment Used: Glaucoma Valve Implantation
  • Number of Patients: 6
  • Published —
This study reported the results obtained from glaucoma drainage device (GDD) implantation in patients with aniridia-related glaucoma.

Clinical Trials

Clinical Trial
Other
  • Status: Recruiting
  • Participants: 20000
  • Start Date: July 2010
Coordination of Rare Diseases at Sanford
Clinical Trial
Device
  • Status: Active, not recruiting
  • Study Type: Device
  • Participants: 72
  • Start Date: April 9, 2003
Clinical Evaluation of Morcher Artificial Iris Diaphragms to Treat Light and Glare Sensitivity in Partial or Complete Aniridia